New York, Jan 5, 2026, 15:21 EST — Regular session
- NewAmsterdam Pharma shares slid about 5% in afternoon trading.
- Two insiders filed Form 144 notices flagging proposed stock sales tied to RSU vesting.
- Biotech stocks lagged the broader market ahead of Friday’s U.S. jobs report and the Jan. 12 start of the J.P. Morgan Healthcare Conference.
Shares of NewAmsterdam Pharma Company N.V. fell about 5% to $33.42 in afternoon trading on Monday. The Nasdaq-listed stock hit an intraday low of $32.68 after opening at $35.15.
The move followed two Form 144 filings that signaled planned sales by company affiliates. In smaller biotech names, even routine insider activity can sway short-term sentiment when liquidity is thinner.
Form 144 is an SEC notice filed before certain holders sell stock under Rule 144, which governs resales of restricted or “control” shares. The filing does not confirm a sale, but it flags potential supply that traders watch.
Chief financial officer M. Ian Somaiya proposed selling 5,118 ordinary shares, while founder and chief scientific officer Johannes Kastelein flagged a planned sale of 6,000 shares, the filings showed. Both listed J.P. Morgan Securities as broker and cited Jan. 5 as the approximate sale date, with aggregate market values of roughly $170,173 and $199,499.
The shares listed on both forms were tied to restricted stock units, a form of stock-based pay that converts into shares when it vests, with vesting dated Jan. 2. Together the proposed sales total 11,118 shares, less than 0.01% of the 113.39 million shares outstanding.
NewAmsterdam’s drop also came as biotech stocks lagged a broader rally led by energy and financials; the SPDR S&P Biotech ETF was down about 1.5%. “The mood has been favoring financial stocks in recent days and as people look beyond tech, this is a sector many are choosing to look toward,” said Steve Sosnick, chief market analyst at Interactive Brokers. Investors now look to Friday’s U.S. nonfarm payrolls report for clues on how soon the Federal Reserve may cut rates. Reuters
Technically, the stock is trading well below its 52-week high of $42 and above its $14.06 low, according to market data. Some traders are watching whether it can hold the low-$30s area after Monday’s slide, with third-party calendars pegging the next earnings update around Feb. 25.
NewAmsterdam is a late-stage biopharmaceutical company developing obicetrapib, an investigational oral drug designed to lower LDL cholesterol, the so-called “bad” cholesterol linked to heart disease. The field is crowded, and investors tend to reward clear trial milestones and regulatory timelines. New Amsterdam
But Form 144 filings can be routine paperwork, and the proposed sales do not always turn into actual trades. Any follow-on insider disclosures or a bigger-than-expected supply overhang would keep pressure on the stock.
